Start here if you're new
what it is
Anixa builds cancer vaccines and cell therapies.
how it gets paid
Last year Anixa Biosciences made $210K in revenue. Breast cancer vaccine research was the main engine at $90K, or 43% of sales.
what just happened
Anixa beat EPS by a penny, but revenue was only $210K.
At a glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
-$0.39 fy2024 eps est
$0M fy2023 rev est
n/a operating margin
xvary composite: 49/100 — below average
What they do
Anixa builds cancer vaccines and cell therapies.
Anixa's edge is a patent that runs into the 2040s. That gives the breast cancer vaccine program more time than most biotech bets get. You are paying for one narrow pipeline, but 5 employees and $0 of debt keep the cash drain small.
How they make money
$210K
annual revenue
Breast cancer vaccine research
$90K
Ovarian cancer vaccine research
$60K
CAR-T therapy development
$40K
Antiviral candidates
$20K
The products that matter
lead clinical program
breast cancer vaccine
Phase 1 · primary valuation driver
This is the asset doing most of the valuation work. With only $210K in annual revenue, positive or negative data here matters more than current operations.
lead asset
second oncology program
CAR-T therapy program
early stage · second shot
This gives you another path to upside, which matters. The catch is timing. Early programs can support the story, but they rarely rescue a lead program that stumbles.
pipeline depth
Key numbers
$95M
market cap
You are paying $95M for a company that sold $210K last year. That gap says the stock trades on hope, not sales.
$210K
annual revenue
This is the full revenue base. It is tiny, so every clinical update matters more than the income statement.
$0
debt
No debt means less lender pressure. It also means funding still leans on equity, which can dilute you.
5
employees
Five employees is not a scale business. It is a science project with a stock ticker.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — risk rank looks solid but balance sheet grade needs watching.
Total return vs. market
Return history isn't available for ANIX right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Anixa beat EPS by a penny, but revenue was only $210K.
EPS came in at -$0.08 versus -$0.09. Revenue still reads like a lab invoice, not a business line.
$210K
revenue
-$0.08
eps
+20.0%
eps vs. last year
the number that mattered
Revenue was $210K. That is the whole top line, and it is tiny next to a $95M market cap.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
ANIX does not have a mature operating business to absorb mistakes. If something breaks, the damage usually shows up fast in the stock because the valuation sits on future milestones rather than present cash generation.
med
the lead program disappoints
The Phase 1 breast cancer vaccine is carrying the narrative. Weak efficacy, safety issues, or a messy readout would hit the core reason many investors are here.
Impact: with only $210K in annual revenue, there is very little operating business underneath the science to cushion a bad result.
med
no debt does not mean no dilution
$0M in long-term debt removes one problem. It does not fund a pipeline. A C++ balance sheet grade grade tells you capital access still matters a lot.
Impact: if cash needs show up before a value-creating milestone, shareholders usually feel it through new equity rather than interest expense.
med
early-stage programs take longer than the stock market wants
Biotech timelines stretch for all sorts of ordinary reasons: enrollment, protocol changes, manufacturing work, and regulator feedback. Ordinary delays still hurt small-cap biotech stocks.
Impact: if milestones slip, the market can compress the valuation long before the science is proven wrong.
med
the stock itself is part of the risk
A 5 / 100 price stability score tells you this name can swing hard between updates. Thin coverage and thin operating proof make each headline louder.
Impact: you can be directionally right on the science and still get thrown around by timing, liquidity, and sentiment.
You are buying pipeline shots, not sales. With $210K of revenue and $0 of debt, one weak readout matters more than a full year of operations.
source: institutional data · regulatory filings · risk analysis
Pay attention to
lead trend
whether the breast cancer vaccine stays the clear center of gravity
Right now the stock trades like the lead program is the company. If management updates shift attention elsewhere, that usually tells you the main timeline slipped or conviction changed.
calendar
annual meeting on march 10, 2026
Useful if it brings specifics. You are listening for trial progress, milestone timing, and any clearer read on how management plans to fund the next leg.
metric
cash burn discipline behind the -$0.08 EPS line
EPS is not the thesis, but it is a clue. If losses widen without corresponding trial progress, the market usually reads that as time getting more expensive.
risk
financing signals before the next major data point
No long-term debt is helpful. The catch is that development still needs capital, and small biotechs often solve that problem by issuing more stock.
Analyst rankings
earnings predictability
50 / 100
Middle of the pack. in human-speak, expect surprises, which is normal when annual revenue is only $210K.
source: institutional data
Institutional activity
institutional ownership data for ANIX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive